2025 H2 -tulosraportti
35 päivää sitten
‧38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
11 t sitten · Muokattu11 t sitten · Muokattu20 Future Norwegian HealthTech and MedTech Leaders (bok) Jasper Kurth and Thor Medical: Scaling Alpha Emitter Production Thor Medical ASA, directed by CEO Jasper Kurth, represents a critical shift in the global supply chain for modern oncology. Kurth, who possesses over fifteen years of leadership experience in the pharmaceutical and med-tech industries, including a significant tenure as General Manager of Radiology Nordics at Bayer, is spearheading the development of the AlphaOne commercial-scale plant at Herøya Industrial Park. The company focuses on the production of alpha-emitters derived from naturally occurring thorium, providing a reliable and environmentally friendly alternative to traditional nuclear reactor-based production. The strategic significance of Thor Medical lies in its proprietary production process, AlphaCycle™, which requires no irradiation, thereby reducing regulatory hurdles and environmental impact. In early 2025, the company secured a NOK 90 Million loan facility from Innovation Norway, complementing a private placement and retail offering that raised approximately NOK 200 Million. This funding ensures that the AlphaOne facility is fully capitalised through its 2026 production ramp-up. https://www.linkedin.com/posts/thor-medical-asa_agelabs-norwegian-healthtech-activity-7445433687615115264-vOZR?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY- 1 päivä sitten · Muokattu1 päivä sitten · Muokattuhttps://www.linkedin.com/posts/c-ray-therpeutics_xdc-2026-recap-activity-7445077543470403584-SM1L?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY 🎤 Several days ago, we took a step — bringing together leading voices from across the global RDC ecosystem at XDC 2026. Isotope producers, ligand innovators, clinical-stage developers. Not just to share a stage, but to see Chengdu. Because Chengdu is not just a conference venue. It has become one of China's most significant radiopharmaceutical hubs — in infrastructure, in policy support, in the speed at which things get built. Visiting the Chengdu Medical City, our guests saw that firsthand. And what they saw in C-Ray was something specific: a single site where the full chain lives — from process development and radiolabeling to cGMP manufacturing and cold-chain logistics. One site. One stop. The conversations on stage reflected exactly why that matters. Ligand platforms are diversifying. Novel isotopes are moving from supply bottleneck to clinical reality. New therapeutic modalities are expanding what radiopharmaceuticals can treat and how. These are not separate trends — they are converging. And they all require the same thing: a manufacturing and development partner who can move with them. That is the role C-Ray was built to play. We are a radiopharmaceutical CRDMO headquartered in Chengdu — at the intersection of China's growing capabilities and the global pipeline that needs them. This is just the beginning. To every speaker, partner, and delegate who made the journey: thank you! 🌹 NorthStar Medical Radioisotopes, LLCThor Medical ASA, Navigo, Oncoinvent ASA And to those who haven't yet — we hope to welcome you to Chengdu, to this industry's next chapter, and to C-Ray. 👐 #XDC2026 #Radiopharmaceuticals #CRDMO #RDC #Chengdu #AlphaTherapy #NuclearMedicine #ligand #isotope #Ac225 #Pb212 #Lu177
·1 päivä sittenThere should be a minimum requirement for volume on the opening/closing auctions. I think it's a joke.
·1 päivä sittenIt would have been better if there was a rule that everyone HAD to show their portfolio for stocks they comment on so that people can decide how seriously they want to take the comment from that particular person. Ideally, everyone has skin in the game. Why is one here pumping up the stock while one themselves only has 4% invested in the stock? If it is as good as one says, then why not have 20, 30 or 40% of their portfolio in TRMED? Perhaps the number of shares and average cost basis would also have been interesting? Someone who has an average cost basis of 0.8kr is perhaps euphoric and should perhaps not give advice to others who have an average cost basis of 3 or 4kr for example?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
35 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11 t sitten · Muokattu11 t sitten · Muokattu20 Future Norwegian HealthTech and MedTech Leaders (bok) Jasper Kurth and Thor Medical: Scaling Alpha Emitter Production Thor Medical ASA, directed by CEO Jasper Kurth, represents a critical shift in the global supply chain for modern oncology. Kurth, who possesses over fifteen years of leadership experience in the pharmaceutical and med-tech industries, including a significant tenure as General Manager of Radiology Nordics at Bayer, is spearheading the development of the AlphaOne commercial-scale plant at Herøya Industrial Park. The company focuses on the production of alpha-emitters derived from naturally occurring thorium, providing a reliable and environmentally friendly alternative to traditional nuclear reactor-based production. The strategic significance of Thor Medical lies in its proprietary production process, AlphaCycle™, which requires no irradiation, thereby reducing regulatory hurdles and environmental impact. In early 2025, the company secured a NOK 90 Million loan facility from Innovation Norway, complementing a private placement and retail offering that raised approximately NOK 200 Million. This funding ensures that the AlphaOne facility is fully capitalised through its 2026 production ramp-up. https://www.linkedin.com/posts/thor-medical-asa_agelabs-norwegian-healthtech-activity-7445433687615115264-vOZR?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY
- 1 päivä sitten · Muokattu1 päivä sitten · Muokattuhttps://www.linkedin.com/posts/c-ray-therpeutics_xdc-2026-recap-activity-7445077543470403584-SM1L?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY 🎤 Several days ago, we took a step — bringing together leading voices from across the global RDC ecosystem at XDC 2026. Isotope producers, ligand innovators, clinical-stage developers. Not just to share a stage, but to see Chengdu. Because Chengdu is not just a conference venue. It has become one of China's most significant radiopharmaceutical hubs — in infrastructure, in policy support, in the speed at which things get built. Visiting the Chengdu Medical City, our guests saw that firsthand. And what they saw in C-Ray was something specific: a single site where the full chain lives — from process development and radiolabeling to cGMP manufacturing and cold-chain logistics. One site. One stop. The conversations on stage reflected exactly why that matters. Ligand platforms are diversifying. Novel isotopes are moving from supply bottleneck to clinical reality. New therapeutic modalities are expanding what radiopharmaceuticals can treat and how. These are not separate trends — they are converging. And they all require the same thing: a manufacturing and development partner who can move with them. That is the role C-Ray was built to play. We are a radiopharmaceutical CRDMO headquartered in Chengdu — at the intersection of China's growing capabilities and the global pipeline that needs them. This is just the beginning. To every speaker, partner, and delegate who made the journey: thank you! 🌹 NorthStar Medical Radioisotopes, LLCThor Medical ASA, Navigo, Oncoinvent ASA And to those who haven't yet — we hope to welcome you to Chengdu, to this industry's next chapter, and to C-Ray. 👐 #XDC2026 #Radiopharmaceuticals #CRDMO #RDC #Chengdu #AlphaTherapy #NuclearMedicine #ligand #isotope #Ac225 #Pb212 #Lu177
- ·1 päivä sittenThere should be a minimum requirement for volume on the opening/closing auctions. I think it's a joke.·1 päivä sittenIt would have been better if there was a rule that everyone HAD to show their portfolio for stocks they comment on so that people can decide how seriously they want to take the comment from that particular person. Ideally, everyone has skin in the game. Why is one here pumping up the stock while one themselves only has 4% invested in the stock? If it is as good as one says, then why not have 20, 30 or 40% of their portfolio in TRMED? Perhaps the number of shares and average cost basis would also have been interesting? Someone who has an average cost basis of 0.8kr is perhaps euphoric and should perhaps not give advice to others who have an average cost basis of 3 or 4kr for example?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
35 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11 t sitten · Muokattu11 t sitten · Muokattu20 Future Norwegian HealthTech and MedTech Leaders (bok) Jasper Kurth and Thor Medical: Scaling Alpha Emitter Production Thor Medical ASA, directed by CEO Jasper Kurth, represents a critical shift in the global supply chain for modern oncology. Kurth, who possesses over fifteen years of leadership experience in the pharmaceutical and med-tech industries, including a significant tenure as General Manager of Radiology Nordics at Bayer, is spearheading the development of the AlphaOne commercial-scale plant at Herøya Industrial Park. The company focuses on the production of alpha-emitters derived from naturally occurring thorium, providing a reliable and environmentally friendly alternative to traditional nuclear reactor-based production. The strategic significance of Thor Medical lies in its proprietary production process, AlphaCycle™, which requires no irradiation, thereby reducing regulatory hurdles and environmental impact. In early 2025, the company secured a NOK 90 Million loan facility from Innovation Norway, complementing a private placement and retail offering that raised approximately NOK 200 Million. This funding ensures that the AlphaOne facility is fully capitalised through its 2026 production ramp-up. https://www.linkedin.com/posts/thor-medical-asa_agelabs-norwegian-healthtech-activity-7445433687615115264-vOZR?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY
- 1 päivä sitten · Muokattu1 päivä sitten · Muokattuhttps://www.linkedin.com/posts/c-ray-therpeutics_xdc-2026-recap-activity-7445077543470403584-SM1L?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY 🎤 Several days ago, we took a step — bringing together leading voices from across the global RDC ecosystem at XDC 2026. Isotope producers, ligand innovators, clinical-stage developers. Not just to share a stage, but to see Chengdu. Because Chengdu is not just a conference venue. It has become one of China's most significant radiopharmaceutical hubs — in infrastructure, in policy support, in the speed at which things get built. Visiting the Chengdu Medical City, our guests saw that firsthand. And what they saw in C-Ray was something specific: a single site where the full chain lives — from process development and radiolabeling to cGMP manufacturing and cold-chain logistics. One site. One stop. The conversations on stage reflected exactly why that matters. Ligand platforms are diversifying. Novel isotopes are moving from supply bottleneck to clinical reality. New therapeutic modalities are expanding what radiopharmaceuticals can treat and how. These are not separate trends — they are converging. And they all require the same thing: a manufacturing and development partner who can move with them. That is the role C-Ray was built to play. We are a radiopharmaceutical CRDMO headquartered in Chengdu — at the intersection of China's growing capabilities and the global pipeline that needs them. This is just the beginning. To every speaker, partner, and delegate who made the journey: thank you! 🌹 NorthStar Medical Radioisotopes, LLCThor Medical ASA, Navigo, Oncoinvent ASA And to those who haven't yet — we hope to welcome you to Chengdu, to this industry's next chapter, and to C-Ray. 👐 #XDC2026 #Radiopharmaceuticals #CRDMO #RDC #Chengdu #AlphaTherapy #NuclearMedicine #ligand #isotope #Ac225 #Pb212 #Lu177
- ·1 päivä sittenThere should be a minimum requirement for volume on the opening/closing auctions. I think it's a joke.·1 päivä sittenIt would have been better if there was a rule that everyone HAD to show their portfolio for stocks they comment on so that people can decide how seriously they want to take the comment from that particular person. Ideally, everyone has skin in the game. Why is one here pumping up the stock while one themselves only has 4% invested in the stock? If it is as good as one says, then why not have 20, 30 or 40% of their portfolio in TRMED? Perhaps the number of shares and average cost basis would also have been interesting? Someone who has an average cost basis of 0.8kr is perhaps euphoric and should perhaps not give advice to others who have an average cost basis of 3 or 4kr for example?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt